GlaxoSmithKline (GSK) is currently in talks to purchase Nuvalent, a biotech firm specializing in cancer treatments, for a sum exceeding $9 billion.
If finalized, this acquisition would be among the largest in GSK's history, reflecting a significant move in the competitive landscape of biotech mergers and acquisitions this year.
The discussions come at a time when the biotech sector is experiencing heightened M&A activity, indicating a potential shift in investment strategies within the pharmaceutical industry.